Novartis is a leading gene therapy developer. In 2019, its SMA treatment Zolgensma became one of the first genetic medicines cleared for use in the U.S., and so far has been the field’s most lucrative product.
Since then, gene therapy has gone through a tumultuous few years. Though other treatments have come to market, the space is still dealing with technological limitations and commercial questions. A market downturn hasn’t helped either, causing several companies to either restructure, pare back research or shut down altogether.
